Tyrosinaemia type I - de novo mutation in liver tissue suppressing an inborn splicing defect

被引:18
作者
Bliksrud, YT [1 ]
Brodtkorb, E
Andresen, PA
van den Berg, IET
Kvittingen, EA
机构
[1] Univ Oslo, Inst Clin Biochem, N-0027 Oslo, Norway
[2] Natl Hosp Norway, Dept Clin Chem, N-0027 Oslo, Norway
[3] Natl Hosp Norway, Dept Pathol, N-0027 Oslo, Norway
[4] Univ Med Ctr Utrecht, Dept Metab & Endocrine Dis, NL-3584 EA Utrecht, Netherlands
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2005年 / 83卷 / 05期
关键词
liver disease; amino acid metabolism; mutagenesis; mosaicism; spliceosome;
D O I
10.1007/s00109-005-0648-2
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Many patients with tyrosinaemia type 1 have a mosaic pattern of fumarylacetoacetase (FAH) immunopositive or immunonegative nodules in liver tissue. This phenomenon has been explained by a spontaneous reversion of the mutation in one allele to a normal genotype, but only a few nodules have been examined. We now report on a Norwegian patient, compound heterozygous for the mutations IVS12g(+5) → a and G(1009→) A, with liver mosaicism, but with an immunopositive nodule in which both primary mutations were intact. In the immunopositive hepatocytes of this nodule, genetic analyses showed a new mutation, C(1061→)A, 6 bp upstream of the primary mutation IVS12g(+5)→ a in the FAH gene. The splicing defect caused by the primary mutation is most likely suppressed by the new mutation due to improvement of the splicing site. In the same liver we demonstrate another nodule of regenerating immunopositive tissue due to reversion of one of the primary mutations to a normal genotype. Together with the original cells this makes a triple mosaicism of hepatocytes with one, two or three point mutations in the FAH gene.
引用
收藏
页码:406 / 410
页数:5
相关论文
共 10 条
[1]   Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy [J].
Arredondo-Vega, FX ;
Santisteban, I ;
Richard, E ;
Bali, P ;
Koleilat, M ;
Loubser, M ;
Al-Ghonaium, A ;
Al-Helali, M ;
Hershfield, MS .
BLOOD, 2002, 99 (03) :1005-1013
[2]   Analysis of canonical and non-canonical splice sites in mammalian genomes [J].
Burset, M ;
Seledtsov, IA ;
Solovyev, VV .
NUCLEIC ACIDS RESEARCH, 2000, 28 (21) :4364-4375
[3]   A missense mutation (Q279R) in the Fumarylacetoacetate Hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation [J].
Dreumont, Natacha ;
Poudrier, Jacques A. ;
Bergeron, Anne ;
Levy, Harvey L. ;
Baklouti, Faouzi ;
Tanguay, Robert M. .
BMC GENETICS, 2001, 2 (1)
[4]  
GOLDSMITH LA, 1989, METABOLIC BASIS INHE, P547
[5]   In vivo reversion to normal of inherited mutations in humans [J].
Hirschhorn, R .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (10) :721-728
[6]   Partial restoration of degraded DNA from archival paraffin-embedded tissues [J].
Imyanitov, EN ;
Grigoriev, MY ;
Gorodinskaya, VM ;
Kuligina, ES ;
Pozharisski, KM ;
Togo, AV ;
Hanson, KP .
BIOTECHNIQUES, 2001, 31 (05) :1000-+
[7]   SELF-INDUCED CORRECTION OF THE GENETIC-DEFECT IN TYROSINEMIA TYPE-I [J].
KVITTINGEN, EA ;
ROOTWELT, H ;
BERGER, R ;
BRANDTZAEG, P .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (04) :1657-1661
[8]   HEREDITARY TYROSINEMIA TYPE-I - SELF-INDUCED CORRECTION OF THE FUMARYLACETOACETASE DEFECT [J].
KVITTINGEN, EA ;
ROOTWELT, H ;
BRANDTZAEG, P ;
BERGAN, A ;
BERGER, R .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1816-1821
[9]   Different clinical forms of hereditary tyrosinemia (Type I) in patients with identical genotypes [J].
Poudrier, J ;
Lettre, F ;
Scriver, CR ;
Larochelle, J ;
Tanguay, RM .
MOLECULAR GENETICS AND METABOLISM, 1998, 64 (02) :119-125
[10]  
ROOTWELT H, 1994, HUM GENET, V94, P235